Stereotactic Surgery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The stereotactic surgery devices market size was valued at USD 29.21 billion in 2025 and is estimated to grow from USD 30.46 billion in 2026 to reach USD 37.58 billion by 2031, at a CAGR of 4.28% during the forecast period (2026-2031). This report is Segmented by Product Type (Linear Accelerator Systems, Gamma Knife Systems, Cyberknife & Robotic Radiosurgery Systems, and More), Application (Brain Tumours, Arteriovenous Malformations, and More), Technology (Frame-Based Systems, and More), End User (Hospitals, Ambulatory Surgery Centres, and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

Global Stereotactic Surgery Devices Market Trends and Insights

Rising Prevalence of Intracranial Tumors & Functional Disorders

Aging populations are creating a steady pipeline of patients requiring precision radiosurgery, while advancements in imaging are uncovering lesions at earlier stages.Clinical studies report a 97.1% local control rate for stereotactic treatment of meningiomas in elderly cohorts, confirming its suitability for patients once considered inoperable. Movement disorders such as Parkinson’s disease and essential tremor are also shifting toward non-invasive stereotactic options that avoid hardware-based deep-brain stimulators. In emerging economies, the increasing availability of MRI scans is driving higher detection rates, thereby reinforcing a multi-regional demand curve. These overlaps between oncology and functional cases are compounding utilization and smoothing the revenue profile for providers.

Shift Toward Minimally Invasive Radiosurgery Over Craniotomy

Hospitals are rewriting surgical pathways as stereotactic procedures deliver comparable tumor control with shorter stays and fewer complications. Cost studies show notable savings in intensive-care days, while patients favor outpatient recovery over traditional craniotomy. The trend is especially visible in skull-base lesions, where open surgery carries high morbidity. As informed-consent discussions pivot to quality-of-life metrics, referral patterns are moving from neurosurgical theaters to radiation suites, cementing stereotactic protocols as first-line options.

CAPEX & Upkeep Costs of Radiosurgery Platforms

A Gamma Knife suite with MRI support can cost approximately USD 9.84 million upfront. At the same time, a CyberKnife room requires at least USD 3.2 million, plus additional build-out expenses - annual maintenance averages 3.13% of the purchase price for LINACs, straining operating budgets. Smaller hospitals struggle to reach break-even case volumes, delaying new installations in lower-income regions. Leasing and multi-institutional equipment sharing are emerging, yet financing hurdles persist.

Other drivers and restraints analyzed in the detailed report include:

• Image-Guided & MRI-LINAC Tech Breakthroughs
• Reimbursement Expansion to Essential Tremor & OCD
• Shortage of Trained Neuro-Radiosurgeons in LICs

Segment Analysis

LINAC platforms held a 37.46% share of the stereotactic surgery devices market in 2025, underscoring their versatility across various tumor sites and fractionation schemes. Hospitals value the dual-use design that supports both conventional radiotherapy and stereotactic boosts without additional capital expenditure. New AI-enabled versions, such as the Evo system showcased in 2024, promise sub-millimeter accuracy while trimming session times.

CyberKnife and other robotic units, projected to grow at 7.44% CAGR, lure centers seeking frameless convenience and intricate beam choreography. The Gamma Knife retains loyalty in pure cranial programs, whereas proton and heavy-ion systems secure niche slots in pediatric applications. As procurement cycles progress, many institutions adopt a hub-and-spoke model: a high-end robotic suite at the flagship site and compact LINAC satellites in feeder clinics, a strategy that broadens the footprint of the stereotactic surgery devices market without overshooting budgets.

Brain tumors represented 44.69% of the stereotactic surgery devices market size in 2025, reflecting decades of protocol refinement and robust outcome data. Multi-disciplinary tumor boards now combine stereotactic radiosurgery with systemic therapies to manage oligometastatic disease.

Functional neurosurgery, however, is the rising star with an 8.37% CAGR forecast. FDA clearance of MRI-guided focused ultrasound for Parkinson’s tremor expanded payer coverage, prompting more centers to add functional service lines. Radiosurgical ablation of epileptogenic foci and psychiatric circuits is entering trial pipelines, hinting at future demand spikes that could reshape the revenue mix across the stereotactic surgery devices market.

Complete Report Scope:

• By Product Type
  • Linear Accelerator (LINAC) Systems
  • Gamma Knife Systems
  • CyberKnife & Robotic Radiosurgery Systems
  • Proton/Heavy-Ion Beam Systems
  • Stereotactic Frames
  • Frameless Navigation Systems
• By Application
  • Brain Tumours
  • Arteriovenous Malformations (AVM)
  • Functional Neurosurgery (Parkinson’s, Epilepsy, Tremor)
  • Spine & Extracranial Metastases
  • Biopsy & Diagnostic Guidance
• By Technology
  • Frame-based Systems
  • Frameless / Image-guided Systems
  • Robotic Radiosurgery Platforms
  • MRI-guided Adaptive Systems
• By End User
  • Hospitals
  • Ambulatory Surgery Centres
  • Cancer & Radiotherapy Centres
  • Academic & Research Institutes
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained a 39.86% share of the stereotactic surgery devices market in 2025, supported by deep reimbursement pools, early clinical adoption, and a dense network of multidisciplinary tumor boards. Robust clinical-trial ecosystems accelerate protocol updates and vendor-provider co-development contracts.

Europe presents a mature but steady landscape where cost-effectiveness audits shape procurement. National health systems emphasize the collection of longitudinal quality-of-life data, prompting providers to favor platforms with adaptive imaging that minimizes toxicity. China’s revised medical-device regulations have opened doors for multinational vendors willing to partner with domestic assemblers, a policy shift that could recalibrate supply chains.

The Asia-Pacific region is the growth nucleus, forecasted to grow at a 6.04% CAGR, as private capital sponsors oncology mega-chains equipped with compact LINAC rooms. The Middle East & Africa and South America are nascent but are building public-private alliances to circumvent capital hurdles. Collectively, demand is migrating toward regions where demographic tailwinds and infrastructure roll-outs align, diversifying the global stereotactic surgery devices market beyond its traditional Western core.

List of Companies Covered in this Report:

• Elekta
• Siemens Healthineers
• Accuray
• Brain Lab
• Monteris Medical
• Medtronic
• Huiheng Medical
• Hitachi
• ViewRay Inc.
• ZAP Surgical Systems
• Mevion Medical Systems
• Ion Beam Applications (IBA)
• GE Healthcare
• Adeor Medical
• FHC Inc.
• Surgical Theater Inc.
• Shinva Medical Instrument
• Changchun Xuyang
• Optivus Proton Therapy

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support